China
/
Pharma
/
SHSE:688658

Youcare Pharmaceutical Group Full Year 2024 Earnings: Misses Expectations

Simply Wall St

March 04, 2025

Youcare Pharmaceutical Group (SHSE:688658) Full Year 2024 Results

Key Financial Results

Revenue: CN¥3.78b (down 9.9% from FY 2023).
Net income: CN¥123.7m (down 33% from FY 2023).
Profit margin: 3.3% (down from 4.4% in FY 2023). The decrease in margin was driven by lower revenue.
EPS: CN¥0.28 (down from CN¥0.41 in FY 2023).

earnings-and-revenue-growth — SHSE:688658 Earnings and Revenue Growth March 4th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Youcare Pharmaceutical Group Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 7.3%. Earnings per share (EPS) also missed analyst estimates by 58%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are down 7.5% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Youcare Pharmaceutical Group that you should be aware of.

If you're looking to trade Youcare Pharmaceutical Group, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.